A case of ALK-rearranged adenocarcinoma with small cell carcinoma-like transformation and resistance to crizotinib

Journal of Thoracic Oncology

Volumn 11, Issue 5, 2016, Pages e55-e58

  Cha, Yoon Jin ^a   Cho, Byoung Chul ^b   Kim, Hye Ryun ^b   Lee, Hye Jeong ^a   Shim, Hyo Sup ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Anaplastic lymphoma kinase; Crizotinib; Lung adenocarcinoma; Resistance; Small cell lung carcinoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CD56 ANTIGEN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ABDOMINAL WALL; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CASE REPORT; CHROMATIN; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HOARSENESS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LYMPHADENOPATHY; MALE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL CELL LUNG CANCER; SMOKING; SUBCUTANEOUS NODULE; TRANSBRONCHIAL LUNG BIOPSY; VOCAL CORD PARALYSIS; ABDOMINAL TUMOR; ADENOCARCINOMA; CELL TRANSFORMATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG TUMOR; PATHOLOGY; SECONDARY;

ABDOMINAL NEOPLASMS; ADENOCARCINOMA; AGED; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SMALL CELL LUNG CARCINOMA;

EID: 84969753096     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.12.097     Document Type: Article

References (5)

1. Toyokawa G, Taguchi K, Ohba T, et al. First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component. J Thorac Oncol. 2012;7:e39-e41.
2. Toyokawa G, Takenoyama M, Taguchi K, et al. An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene. Lung Cancer. 2013;81:487-490.
3. Omachi N, Shimizu S, Kawaguchi T, et al. A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor cri-zotinib. J Thorac Oncol. 2014;9:e40-e42.
4. Kobayashi Y, Sakao Y, Ito S, et al. Transformation to sar-comatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies. J Thorac Oncol. 2013;8:e75-e78.
5. Oser MG, Niederst MJ, Sequist LV, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16:e165-e172.